Sinclair Pharma Share News (SPH)

Shares in Sinclair Pharma are rising on the back of the collaboration with Invidia that will help to commercialise Sinclair's dermatology brands in Asia Pacific. The deal covers 11 markets and it is expected to last 20 years. The drugs will be launched over a three year period. Drug developer Skyepharma continues to fall following last Friday's trading statement saying that revenues will fall in 2011. This is because of non-recurring manufacturing revenues in 2010. Skyepharma remains confident that asthma treatment Flutiform will be launched in Europe in the second half of 2011. FTSE TechMARK - RisersSinclair Pharma (SPH) 34.00p +7.09%Wolfson Microelectronics (WLF) 267.50p +2.39%BATM Advanced Communications Ltd. (BVC) 21.75p +2.35%Promethean World (PRW) 57.50p +2.22%Biocompatibles International (BII) 395.00p +1.80%Kofax (KFX) 283.25p +0.98%Psion (PON) 94.25p +0.80%Phoenix IT Group (PNX) 264.50p +0.38%Kewill (KWL) 88.50p +0.28%Xaar (XAR) 228.00p +0.22%FTSE TechMARK - FallersSkyepharma (SKP) 30.00p -4.76%DRS Data & Research Services (DRS) 20.25p -3.57%Consort Medical (CSRT) 463.25p -2.93%ProStrakan Group (PSK) 85.50p -2.84%Dialight (DIA) 460.00p -2.65%E2V Technologies (E2V) 94.25p -2.33%Emblaze Ltd. (BLZ) 47.00p -2.08%Alterian (ALN) 187.00p -1.84%Innovation Group (TIG) 13.75p -1.79%Anite (AIE) 56.00p -1.75%